ClinicalTrials.gg
CompletedNCT03039686Updated Dec 21, 2020Results posted

Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy

A Phase 2/3 interventional study of RO7239361 and Placebo for RO7239361 in Duchenne Muscular Dystrophy, sponsored by Hoffmann-La Roche. Completed at 44 sites in 13 countries. Open to male participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2020-12-21.

Sponsored by Hoffmann-La Roche · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
17th of 171
166 · median 25
Started
2017
with 10 others
Phase 2/3
8 of 232
1 open now
Registered
112th of 232
by date

Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 17th largest by enrollment of the 171 interventional ones that give a count, is one of 11 that started in 2017, is one of 8 in phase 2/3, and was the 112th registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 6 Years to 11 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of two different weekly doses of RO7239361 in ambulatory boys with Duchenne Muscular Dystrophy (DMD).

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • muscular dystrophy
  • Duchenne's Muscular Dystrophy
  • DMD
04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with DMD by confirmed medical history and genetic testing
  • Able to walk without assistance
  • Minimum North Star Ambulatory Assessment score of 15 at screening
  • Able to walk up 4 stairs in 8 seconds or less
  • Weigh at least 15 kg (33 lbs)
  • Taking for DMD

Exclusion criteria

Exclusion Criteria:

  • Any behavior or mental issue that will affect the ability to complete the required study procedures
  • Previously or currently taking medications like androgens or human growth hormone
  • Use of a ventilator during the day
  • Unable to have blood samples collected or receive an injection under the skin
  • Concomitant or previous participation at any time in a gene therapy study

Other protocol defined Inclusion/Exclusion Criteria could apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    RO7239361 Low Dose

    Participants received low dose RO7239361 SC on specified days of the 48-week DB period. Following the DB period participants received low dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.

    Drug: RO7239361

  • Experimental
    RO7239361 High Dose

    Participants received high dose RO7239361 SC on specified days of the 48-week DB period. Following the DB period participants received high dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.

    Drug: RO7239361

  • Placebo comparator
    Placebo

    Participants received matching placebo solution subcutaneously (SC) on specified days of the 48-week double-blind (DB) period. Following the DB period participants received low dose or high dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.

    Drug: Placebo for RO7239361

Interventions

  • Take RO7239361 subcutaneously on specified days over a 48 week blinded period

  • DrugPlacebo for RO7239361

    Take placebo subcutaneously on specified days over a 48 week blinded period

06

What researchers measure

Primary outcomes

  1. Baseline for the North Star Ambulatory Assessment (NSAA) Total Score

    The NSAA is a functional scale specifically designed for ambulant boys with Duchenne muscular dystrophy (DMD) that can provide information about motor function. The NSAA is a 17-item test of standing, ability to transition from lying to sitting, sitting to standing, and other mobility assessments. Each of the 17 items is evaluated on an ordinal scale of 0-2: 0 = unable to achieve independently, 1 = modified method but achieves goal independent of physical assistance from another, or 2 = normal with no obvious modification of activity. Total score range is 0 to 34. Higher scores reflect better performance.

    Time frame: Baseline

  2. Change From Baseline in the North Star Ambulatory Assessment (NSAA) Total Score at Week 48

    The NSAA is a functional scale specifically designed for ambulant boys with Duchenne muscular dystrophy (DMD) that can provide information about motor function. The NSAA is a 17-item test of standing, ability to transition from lying to sitting, sitting to standing, and other mobility assessments. Each of the 17 items is evaluated on an ordinal scale of 0-2: 0 = unable to achieve independently, 1 = modified method but achieves goal independent of physical assistance from another, or 2 = normal with no obvious modification of activity. Total score range is 0 to 34. Higher scores reflect better performance. A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Baseline Time for 4 Stair Climb

    The time to complete the 4 stair climb was measured at baseline.

    Time frame: Baseline

  2. Change From Baseline at Week 48 in 4 Stair Climb Velocity (4SCV)

    4SCV was calculated as the ratio of the number of stairs climbed (4) divided by the number of seconds taken to complete the 4-stair climb. The results were converted into velocity (distance/time). A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).

    Time frame: Baseline, Week 48

  3. Baseline for the Time to Stand From Supine

    The time required for a participant to stand from supine position. A longer time reflects a worse outcome.

    Time frame: Baseline

  4. Change From Baseline at Week 48 in Stand From Supine Velocity

    The time required for a participant to stand from supine position. A longer time reflects a worse outcome. A negative change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).

    Time frame: Baseline, Week 48

  5. Baseline Time for 10 Meter Walk/Run

    The time required for a participant to run or walk a distance of 10 meters as quickly as possible. A longer time reflects a worse outcome.

    Time frame: Baseline

  6. Change From Baseline at Week 48 in 10 M Walk/Run Velocity

    The time required for a participant to run or walk a distance of 10 meters as quickly as possible calculated as velocity (distance/time). A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).

    Time frame: Baseline, Week 48

  7. Baseline for the Pediatric Outcome Data Collection Instrument (PODCI) Transfer and Basic Mobility Subscale

    The PODCI is designed to be completed by the parent/guardian of a child who has knowledge of the child's conditions. The Transfer and Basic Mobility scale is one of the subscales of the PODCI. The results are standardized into a scale of 0-100 with a higher score reflecting better performance.

    Time frame: Baseline

  8. Change From Baseline at Week 48 in Pediatric Outcome Data Collection Instrument (PODCI) Transfer and Basic Mobility Subscale

    The PODCI is designed to be completed by the parent/guardian of a child who has knowledge of the child's conditions. The Transfer and Basic Mobility scale is one of the subscales of the PODCI. The results are standardized into a scale of 0-100 with a higher score reflecting better performance. A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).

    Time frame: Baseline, Week 48

  9. Change From Baseline at Week 48 in Proximal Lower Extremity Flexor Strength

    Proximal lower extremity flexor (knee extension and knee flexion) strength was measured using manual myometry. A higher score reflects a better outcome. A positive change from baseline indicates an improvement.

    Time frame: Baseline, Week 48

  10. Baseline for the 6 Minute Walk Distance (6MWD)

    The 6MWD measured the distance a participant was able to traverse while walking for 6 minutes. A longer distance reflects a better outcome.

    Time frame: Baseline

  11. Change From Baseline at Week 48 in 6 Minute Walk Distance (6MWD)

    The 6MWD measured the distance a participant was able to traverse while walking for 6 minutes. A longer distance reflects a better outcome. A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).

    Time frame: Baseline, Week 48

  12. Percentage of Participants for Each Clinical Global Impression of Change (CGI-C) Assessment Status at Week 48

    The CGI-C was used to assess the participant's overall condition on a 7-point scale, using the status markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse or very much worse" at Week 48 as compared to baseline.

    Time frame: Baseline, Week 48

  13. Change From Baseline at Week 48 in 95th Percentile Stride Velocity

    Stride velocity was recorded with the ActiMyo device in a subset of the overall study population. The ActiMyo device measures the daily movement and activity levels of the participant. The device consists of two sensors worn on each ankle. A higher velocity reflects a better outcome. A positive change from baseline indicates an improvement.

    Time frame: Baseline, Week 48

  14. Number of Participants With Adverse Events (AEs)

    An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: During DB period (48 weeks) and Whole study (up to approximately 34 months)

  15. Number of Participants With AEs Leading to Discontinuation

    An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Reported here is the number of participants with AEs that led to study discontinuation.

    Time frame: During DB period (48 weeks) and Whole study (up to approximately 34 months)

07

Results

Posted Dec 21, 2020

Participant flow

Double-blind Period
Participant flow — Double-blind Period
MilestonePlaceboRO7239361 Low DoseRO7239361 High Dose
Started565555
Completed292632
Not completed272923
Withdrew: Administrative reason by sponsor242521
Withdrew: Subject request to discontinue study treatment120
Withdrew: Withdrawal by subject221
Withdrew: Death001
Open Label Period
Participant flow — Open Label Period
MilestonePlaceboRO7239361 Low DoseRO7239361 High Dose
Started03842
Completed db, did not start ol223
Completed000
Not completed03842
Withdrew: Administrative reason by sponsor03441
Withdrew: Subject request to discontinue study treatment010
Withdrew: Withdrawal by subject031

Outcome measures

PrimaryBaseline for the North Star Ambulatory Assessment (NSAA) Total Score

The NSAA is a functional scale specifically designed for ambulant boys with Duchenne muscular dystrophy (DMD) that can provide information about motor function. The NSAA is a 17-item test of standing, ability to transition from lying to sitting, sitting to standing, and other mobility assessments. Each of the 17 items is evaluated on an ordinal scale of 0-2: 0 = unable to achieve independently, 1 = modified method but achieves goal independent of physical assistance from another, or 2 = normal with no obvious modification of activity. Total score range is 0 to 34. Higher scores reflect better performance.

Time frame:
Baseline
Reported as:
Mean · score on a scale
Baseline for the North Star Ambulatory Assessment (NSAA) Total Score
score on a scalePlaceboRO7239361 Low DoseRO7239361 High Dose
Baseline for the North Star Ambulatory Assessment (NSAA) Total Score23.1 ± 6.424.5 ± 5.522.7 ± 6.7
PrimaryChange From Baseline in the North Star Ambulatory Assessment (NSAA) Total Score at Week 48

The NSAA is a functional scale specifically designed for ambulant boys with Duchenne muscular dystrophy (DMD) that can provide information about motor function. The NSAA is a 17-item test of standing, ability to transition from lying to sitting, sitting to standing, and other mobility assessments. Each of the 17 items is evaluated on an ordinal scale of 0-2: 0 = unable to achieve independently, 1 = modified method but achieves goal independent of physical assistance from another, or 2 = normal with no obvious modification of activity. Total score range is 0 to 34. Higher scores reflect better performance. A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · score on a scale
Change From Baseline in the North Star Ambulatory Assessment (NSAA) Total Score at Week 48
score on a scalePlaceboRO7239361 Low DoseRO7239361 High Dose
Change From Baseline in the North Star Ambulatory Assessment (NSAA) Total Score at Week 48-2.99 ± 0.65-3.44 ± 0.67-2.41 ± 0.64
Statistical analysis
  • Placebo vs RO7239361 Low Dose · Mean difference (final values): -0.45 · 95% CI -2.17 to 1.27Based on the MMRM using an unstructured covariance matrix -change = Baseline + Age Interactive response system (IXRS) Stratum + Corticosteroid Regimen IXRS Stratum + Analysis Visit\*Treatment.
  • Placebo vs RO7239361 High Dose · Mean difference (final values): 0.58 · 95% CI -1.10 to 2.26Based on the MMRM using an unstructured covariance matrix -change = Baseline + Age IXRS Stratum + Corticosteroid Regimen IXRS Stratum + Analysis Visit\*Treatment.
SecondaryBaseline Time for 4 Stair Climb

The time to complete the 4 stair climb was measured at baseline.

Time frame:
Baseline
Reported as:
Mean · seconds (secs)
Baseline Time for 4 Stair Climb
seconds (secs)PlaceboRO7239361 Low DoseRO7239361 High Dose
Baseline Time for 4 Stair Climb3.81 ± 1.553.85 ± 1.613.92 ± 1.91
SecondaryChange From Baseline at Week 48 in 4 Stair Climb Velocity (4SCV)

4SCV was calculated as the ratio of the number of stairs climbed (4) divided by the number of seconds taken to complete the 4-stair climb. The results were converted into velocity (distance/time). A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · stairs/sec
Change From Baseline at Week 48 in 4 Stair Climb Velocity (4SCV)
stairs/secPlaceboRO7239361 Low DoseRO7239361 High Dose
Change From Baseline at Week 48 in 4 Stair Climb Velocity (4SCV)-0.15 ± 0.07-0.15 ± 0.07-0.07 ± 0.07
Statistical analysis
  • Placebo vs RO7239361 Low Dose · Mean difference (final values): -0.00 · 95% CI -0.21 to 0.20Based on the MMRM using an unstructured covariance matrix - change = Baseline + Age IXRS Stratum + Corticosteroid Regimen IXRS Stratum + Analysis Visit\*Treatment.
  • Placebo vs RO7239361 High Dose · Mean difference (final values): 0.08 · 95% CI -0.12 to 0.27Based on the MMRM using an unstructured covariance matrix - change = Baseline + Age IXRS Stratum + Corticosteroid Regimen IXRS Stratum + Analysis Visit\*Treatment.
SecondaryBaseline for the Time to Stand From Supine

The time required for a participant to stand from supine position. A longer time reflects a worse outcome.

Time frame:
Baseline
Reported as:
Mean · secs
Baseline for the Time to Stand From Supine
secsPlaceboRO7239361 Low DoseRO7239361 High Dose
Baseline for the Time to Stand From Supine6.28 ± 4.756.15 ± 4.077.24 ± 9.22
SecondaryChange From Baseline at Week 48 in Stand From Supine Velocity

The time required for a participant to stand from supine position. A longer time reflects a worse outcome. A negative change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · 1/sec
Change From Baseline at Week 48 in Stand From Supine Velocity
1/secPlaceboRO7239361 Low DoseRO7239361 High Dose
Change From Baseline at Week 48 in Stand From Supine Velocity-0.05 ± 0.01-0.02 ± 0.01-0.02 ± 0.01
Statistical analysis
  • Placebo vs RO7239361 Low Dose · Mean difference (final values): 0.03 · 95% CI -0.00 to 0.06Based on the MMRM using an unstructured covariance matrix - change = Baseline + Age IXRS Stratum + Corticosteroid Regimen IXRS Stratum + Analysis Visit\*Treatment.
  • Placebo vs RO7239361 High Dose · Mean difference (final values): 0.03 · 95% CI -0.00 to 0.06Based on the MMRM using an unstructured covariance matrix - change = Baseline + Age IXRS Stratum + Corticosteroid Regimen IXRS Stratum + Analysis Visit\*Treatment.
SecondaryBaseline Time for 10 Meter Walk/Run

The time required for a participant to run or walk a distance of 10 meters as quickly as possible. A longer time reflects a worse outcome.

Time frame:
Baseline
Reported as:
Mean · secs
Baseline Time for 10 Meter Walk/Run
secsPlaceboRO7239361 Low DoseRO7239361 High Dose
Baseline Time for 10 Meter Walk/Run5.38 ± 1.485.51 ± 1.685.68 ± 2.30
SecondaryChange From Baseline at Week 48 in 10 M Walk/Run Velocity

The time required for a participant to run or walk a distance of 10 meters as quickly as possible calculated as velocity (distance/time). A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · m/sec
Change From Baseline at Week 48 in 10 M Walk/Run Velocity
m/secPlaceboRO7239361 Low DoseRO7239361 High Dose
Change From Baseline at Week 48 in 10 M Walk/Run Velocity-0.23 ± 0.06-0.14 ± 0.07-0.23 ± 0.06
Statistical analysis
  • Placebo vs RO7239361 Low Dose · Mean difference (final values): 0.09 · 95% CI -0.08 to 0.27Based on the MMRM using an unstructured covariance matrix - change = Baseline + Age IXRS Stratum + Corticosteroid Regimen IXRS Stratum + Analysis Visit\*Treatment.
  • Placebo vs RO7239361 High Dose · Mean difference (final values): 0.00 · 95% CI -0.17 to 0.18Based on the MMRM using an unstructured covariance matrix - change = Baseline + Age IXRS Stratum + Corticosteroid Regimen IXRS Stratum + Analysis Visit\*Treatment.
SecondaryBaseline for the Pediatric Outcome Data Collection Instrument (PODCI) Transfer and Basic Mobility Subscale

The PODCI is designed to be completed by the parent/guardian of a child who has knowledge of the child's conditions. The Transfer and Basic Mobility scale is one of the subscales of the PODCI. The results are standardized into a scale of 0-100 with a higher score reflecting better performance.

Time frame:
Baseline
Reported as:
Mean · score on a scale
Baseline for the Pediatric Outcome Data Collection Instrument (PODCI) Transfer and Basic Mobility Subscale
score on a scalePlaceboRO7239361 Low DoseRO7239361 High Dose
Baseline for the Pediatric Outcome Data Collection Instrument (PODCI) Transfer and Basic Mobility Subscale85.59 ± 10.2186.54 ± 9.5284.47 ± 14.76
SecondaryChange From Baseline at Week 48 in Pediatric Outcome Data Collection Instrument (PODCI) Transfer and Basic Mobility Subscale

The PODCI is designed to be completed by the parent/guardian of a child who has knowledge of the child's conditions. The Transfer and Basic Mobility scale is one of the subscales of the PODCI. The results are standardized into a scale of 0-100 with a higher score reflecting better performance. A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 48 in Pediatric Outcome Data Collection Instrument (PODCI) Transfer and Basic Mobility Subscale
score on a scalePlaceboRO7239361 Low DoseRO7239361 High Dose
Change From Baseline at Week 48 in Pediatric Outcome Data Collection Instrument (PODCI) Transfer and Basic Mobility Subscale-5.47 ± 1.79-7.47 ± 1.83-4.51 ± 1.77
Statistical analysis
  • Placebo vs RO7239361 Low Dose · Mean difference (final values): -2.00 · 95% CI -6.76 to 2.77Based on the MMRM using an unstructured covariance matrix - change = Baseline + Age IXRS Stratum + Corticosteroid Regimen IXRS Stratum + Analysis Visit\*Treatment.
  • Placebo vs RO7239361 High Dose · Mean difference (final values): 0.96 · 95% CI -3.71 to 5.63Based on the MMRM using an unstructured covariance matrix - change = Baseline + Age IXRS Stratum + Corticosteroid Regimen IXRS Stratum + Analysis Visit\*Treatment.
SecondaryChange From Baseline at Week 48 in Proximal Lower Extremity Flexor Strength

Proximal lower extremity flexor (knee extension and knee flexion) strength was measured using manual myometry. A higher score reflects a better outcome. A positive change from baseline indicates an improvement.

Time frame:
Baseline, Week 48
Reported as:
Mean · kilogram (kg)
Change From Baseline at Week 48 in Proximal Lower Extremity Flexor Strength
kilogram (kg)PlaceboRO7239361 Low DoseRO7239361 High Dose
Baseline: Knee Extenders5.58 ± 2.876.25 ± 3.635.76 ± 3.53
Change from Baseline at Week 48: Knee Extenders-1.19 ± 2.13-0.47 ± 2.43-0.88 ± 2.97
Baseline: Knee Flexors5.04 ± 2.585.70 ± 3.085.04 ± 2.72
Change from Baseline at Week 48: Knee Flexors0.15 ± 2.240.08 ± 2.53-0.13 ± 2.29
SecondaryBaseline for the 6 Minute Walk Distance (6MWD)

The 6MWD measured the distance a participant was able to traverse while walking for 6 minutes. A longer distance reflects a better outcome.

Time frame:
Baseline
Reported as:
Mean · meters (m)
Baseline for the 6 Minute Walk Distance (6MWD)
meters (m)PlaceboRO7239361 Low DoseRO7239361 High Dose
Baseline for the 6 Minute Walk Distance (6MWD)388.33 ± 69.59399.73 ± 68.35370.73 ± 93.35
SecondaryChange From Baseline at Week 48 in 6 Minute Walk Distance (6MWD)

The 6MWD measured the distance a participant was able to traverse while walking for 6 minutes. A longer distance reflects a better outcome. A positive change from baseline indicates an improvement. Based on the mixed-effect model of repeated measures (MMRM).

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · meters (m)
Change From Baseline at Week 48 in 6 Minute Walk Distance (6MWD)
meters (m)PlaceboRO7239361 Low DoseRO7239361 High Dose
Change From Baseline at Week 48 in 6 Minute Walk Distance (6MWD)-41.3 ± 8.7-39.6 ± 9.0-30.0 ± 8.7
Statistical analysis
  • Placebo vs RO7239361 Low Dose · Mean difference (final values): 1.7 · 95% CI -21.1 to 24.6Based on the MMRM using an unstructured covariance matrix - change = Baseline + Age IXRS Stratum + Corticosteroid Regimen IXRS Stratum + Analysis Visit\*Treatment.
  • Placebo vs RO7239361 High Dose · Mean difference (final values): 11.3 · 95% CI -11.0 to 33.6Based on the MMRM using an unstructured covariance matrix - change = Baseline + Age IXRS Stratum + Corticosteroid Regimen IXRS Stratum + Analysis Visit\*Treatment.
SecondaryPercentage of Participants for Each Clinical Global Impression of Change (CGI-C) Assessment Status at Week 48

The CGI-C was used to assess the participant's overall condition on a 7-point scale, using the status markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse or very much worse" at Week 48 as compared to baseline.

Time frame:
Baseline, Week 48
Reported as:
Number · percentage of participants
Percentage of Participants for Each Clinical Global Impression of Change (CGI-C) Assessment Status at Week 48
percentage of participantsPlaceboRO7239361 Low DoseRO7239361 High Dose
Very much improved000
Much improved5.62.73.2
Minimally improved13.913.519.4
No change58.354.151.6
Minimally worse16.718.922.6
Much worse5.610.83.2
Very much worse000
SecondaryChange From Baseline at Week 48 in 95th Percentile Stride Velocity

Stride velocity was recorded with the ActiMyo device in a subset of the overall study population. The ActiMyo device measures the daily movement and activity levels of the participant. The device consists of two sensors worn on each ankle. A higher velocity reflects a better outcome. A positive change from baseline indicates an improvement.

Time frame:
Baseline, Week 48
Reported as:
Mean · m/sec
Change From Baseline at Week 48 in 95th Percentile Stride Velocity
m/secPlaceboRO7239361 Low DoseRO7239361 High Dose
Baseline1.69 ± 0.331.54 ± 0.351.57 ± 0.46
Change from Baseline at Week 48-0.25 ± 0.39-0.22 ± 0.22-0.28 ± 0.29
SecondaryNumber of Participants With Adverse Events (AEs)

An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Time frame:
During DB period (48 weeks) and Whole study (up to approximately 34 months)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsPlacebo DBRO7239361 Low Dose DBRO7239361 High Dose DBRO7239361 Low DoseRO7239361 High Dose Whole Study
Double-Blind Period464849——
Whole Study———5756
SecondaryNumber of Participants With AEs Leading to Discontinuation

An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Reported here is the number of participants with AEs that led to study discontinuation.

Time frame:
During DB period (48 weeks) and Whole study (up to approximately 34 months)
Reported as:
Number · participants
Number of Participants With AEs Leading to Discontinuation
participantsPlacebo DBRO7239361 Low Dose DBRO7239361 High Dose DBRO7239361 Low DoseRO7239361 High Dose
Double-Blind Period000——
Whole Study———00

Adverse events

Collected over Up to approximately 34 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo DB0/56 (0%)3/56 (5.4%)43/56 (76.8%)
RO7239361 Low Dose DB0/55 (0%)2/55 (3.6%)43/55 (78.2%)
RO7239361 High Dose DB1/55 (1.8%)4/55 (7.3%)47/55 (85.5%)
Placebo, Then RO7239361 Low Dose OL0/14 (0%)0/14 (0%)8/14 (57.1%)
Placebo, Then RO7239361 High Dose OL0/13 (0%)0/13 (0%)7/13 (53.8%)
RO7239361 Low Dose, Then RO7239361 Low Dose OL0/24 (0%)0/24 (0%)13/24 (54.2%)
RO7239361 High Dose, Then RO7239361 High Dose OL0/29 (0%)0/29 (0%)12/29 (41.4%)
Most frequent serious events
Most frequent serious events
EventPlacebo DBRO7239361 Low Dose DBRO7239361 High Dose DBPlacebo, Then RO7239361 Low Dose OLPlacebo, Then RO7239361 High Dose OLRO7239361 Low Dose, Then RO7239361 Low Dose OLRO7239361 High Dose, Then RO7239361 High Dose OL
Cardiac arrestCardiac disorders0/560/551/550/140/130/240/29
Supraventricular tachycardiaCardiac disorders0/560/551/550/140/130/240/29
HyperbilirubinaemiaHepatobiliary disorders0/560/551/550/140/130/240/29
Viral infectionInfections and infestations0/561/550/550/140/130/240/29
Humerus fractureInjury, poisoning and procedural complications0/561/550/550/140/130/240/29
OverdoseInjury, poisoning and procedural complications0/560/551/550/140/130/240/29
MyocarditisCardiac disorders1/560/550/550/140/130/240/29
Influenza like illnessGeneral disorders1/560/550/550/140/130/240/29
Gastrointestinal viral infectionInfections and infestations1/560/550/550/140/130/240/29
HypocalcaemiaMetabolism and nutrition disorders1/560/550/550/140/130/240/29
Most frequent other events
Showing 10 of 54
Most frequent other events
EventPlacebo DBRO7239361 Low Dose DBRO7239361 High Dose DBPlacebo, Then RO7239361 Low Dose OLPlacebo, Then RO7239361 High Dose OLRO7239361 Low Dose, Then RO7239361 Low Dose OLRO7239361 High Dose, Then RO7239361 High Dose OL
HeadacheNervous system disorders9/5614/5510/551/140/132/242/29
NasopharyngitisInfections and infestations13/5613/5513/552/140/130/242/29
Injection site erythemaGeneral disorders8/5611/5512/550/143/132/241/29
DiarrhoeaGastrointestinal disorders3/5610/554/550/140/131/242/29
CoughRespiratory, thoracic and mediastinal disorders10/568/557/551/140/130/241/29
PyrexiaGeneral disorders8/569/558/552/141/133/241/29
Muscle spasmsMusculoskeletal and connective tissue disorders1/562/552/551/142/130/241/29
VomitingGastrointestinal disorders6/568/556/550/140/133/242/29
Pain in extremityMusculoskeletal and connective tissue disorders2/564/558/551/140/130/240/29
Ligament sprainInjury, poisoning and procedural complications4/561/551/552/140/133/241/29

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboRO7239361 Low DoseRO7239361 High DoseTotal
Mean8.4 ± 1.78.5 ± 1.88.4 ± 1.58.5 ± 1.7
Age, Customized
Age, Customized(participants)PlaceboRO7239361 Low DoseRO7239361 High DoseTotal
Children (6-11 years)565555166
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRO7239361 Low DoseRO7239361 High DoseTotal
Female0000
Male565555166
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboRO7239361 Low DoseRO7239361 High DoseTotal
Hispanic or Latino75618
Not Hispanic or Latino434143127
Unknown or Not Reported69621
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboRO7239361 Low DoseRO7239361 High DoseTotal
Asian97723
Native Hawaiian or other Pacific Islander0011
White424545132
Other53210
08

Study locations

44 sites
  • Neuromuscular Research Center
    Phoenix, Arizona 85028, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • Yale University School of Medicine ; Pulmonary & Critical Care
    New Haven, Connecticut 06510, United States
  • University of Florida
    Gainesville, Florida 32607, United States
  • Nemours Children's Hospital
    Orlando, Florida 32827, United States
  • Rare Disease Research, LLC
    Atlanta, Georgia 30318, United States
  • Rush University Medical Center - PPDS
    Chicago, Illinois 60612, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Kennedy Krieger Institute
    Baltimore, Maryland 21205, United States
  • University of Massachusetts Memorial Childrens Medical Center; Department of Neurology
    Worcester, Massachusetts 01655, United States
  • Saint Louis Children's Hospital
    Saint Louis, Missouri 63110, United States
  • Las Vegas Clinic
    Las Vegas, Nevada 89145, United States
  • Cincinnati Childrens Hospital Medical Center;Investigational Pharmacy
    Cincinnati, Ohio 45229, United States
  • Nationwide Childrens Hospital; Research Institute at Nationwide Childrens Hospital
    Columbus, Ohio 43205, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Instituto centenario
    Buenos Aires, C1204AAD, Argentina
  • Children's Hospital Westmead; Paediatrics & Child Health
    Westmead, New South Wales 2145, Australia
  • Lady Cilento Children's Hospital; Neurosciences Department
    South Brisbane, Queensland 4101, Australia
  • Royal Children's Hospital
    Parkville, Victoria 3052, Australia
  • UZ Gent
    Gent, 9000, Belgium
  • London Health Sciences Centre; Children's Hospital; Pediatrics
    London, Ontario N6A 5W9, Canada
  • Children'S Hospital of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
  • Hospices Civils de Lyon
    Lyon, 69004, France
  • Hotel Dieu; Service Pharmacie Essais Cliniques
    Nantes, 44093, France
  • Hopital Armand Trousseau; centre reference Maladies Neuro-musculaires Est parisien Neuropediatrie
    Paris Cedex 12, 75571, France
  • Hopitaux Universitaires de Strasbourg
    Strasbourg, 67091, France
  • Universitatsklinikum Essen; Innere Klinik
    Essen, 45122, Germany
  • Fondazione Serena Onlus - CENTRO CLINICO NEMO
    Milano, Emilia-Romagna 20162, Italy
  • Fondazione Policlinico Universitario A Gemelli; Servizio di Farmacia
    Rome, Lazio 00168, Italy
  • Az. Osp. Universitaria Pol. G. Martino; Dip. Neuroscienze, Scienze Psichiatriche e Anest.
    Messina, Sicilia 98125, Italy
  • Hyogo College of Medicine Hospital
    Hyogo, 663-8501, Japan
  • Miyagi Children's Hospital
    Miyagi, 989-3126, Japan
  • Shinshu University Hospital
    Nagano, 390-8621, Japan
  • National Hospital Organization Osaka Toneyama Medical Center
    Osaka, 560-8552, Japan
  • National Center of Neurology and Psychiatry
    Tokyo, 187-8551, Japan
  • Leids Universitair Medisch Centrum
    Leiden, 2333 ZA, Netherlands
  • Radboud University Nijmegen Medical Centre; Ophthalmology
    Nijmegen, 6525 EX, Netherlands
  • Hospital Sant Joan De Deu
    Esplugues De Llobregas, Barcelona 08950, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia; Servicio de Farmacia
    Valencia, 46026, Spain
  • Drottning Silvias Barn- och ungdomssjukhus; Kliniken for barnmedicin
    Goeteborg, 41685, Sweden
  • Alder Hey Children s Hospital; Department of Pediatrics
    Liverpool, L12 2AP, United Kingdom
  • UCL Institute of Child Health & Great Ormond Street Hospital for Children
    London, WC1N 1EH, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Apr 2020, 33 months.

Results were first posted in Dec 2020, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2017
First posted
Feb 1, 2017
StartActual
Jul 6, 2017
Primary completionActual
Apr 28, 2020
CompletionActual
Apr 28, 2020
Results first posted
Dec 21, 2020
Last update
Dec 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03039686
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 1, 2017
Start date
Jul 6, 2017
Primary completion
Apr 28, 2020
Completion
Apr 28, 2020
Results posted
Dec 21, 2020
Last update
Dec 21, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Taldefgrobep alfa

Start the discussion